While about 30% of HR+/HER2+ tumors are HER2-enriched, with relation to high HER2/EGFR-pathway activation, high proliferation rate, and an immune-activated stroma with elevated tumor-infiltrating lymphocytes (TILs) levels (6). This evidence concerns the gene ERBB2 and neoplasm.